IXICO plc (IXI) AI Stock Analysis

• Market Cap: £7.23M
• Dividend Yield: N/A
• Average Volume (3M): 123.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 13.32%
• EPS Growth: 55.07%
• Country: UK
• Employees: 81
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 92,668,594
• 10 Day Avg. Volume: 82,815
• 30 Day Avg. Volume: 123,868
• PEG Ratio: 0.13
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 1.81
• P/FCF Ratio: -12.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): £7.50M

• Rating: 51 Neutral
• Price Target: 7.50 p ▼(-36.17% Downside)
• Action: Reiterated Date: 02/22/26
• Date: Action: Reiterated 02/22/26

The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.

Positive Factors

Specialized neuroimaging analytics

IXICO's focused business model in neuroimaging and biomarker analytics creates a durable competitive niche. Deep technical expertise and regulatory-aligned services support repeat contract demand from pharma/biotech, making revenue streams sticky and aligned with long-term CNS drug development trends.

Order book expansion and revenue momentum

A materially larger order book and a reported 1.5 book-to-bill ratio provide multi-quarter revenue visibility and demonstrate durable client demand. This backlog supports management's 15% revenue guidance and reduces near-term sales risk while enabling operational scaling toward profitability thresholds.

Conservative balance sheet and cash buffer

Low leverage and a positive net asset position give IXICO financial flexibility to fund platform investment and take on longer trials without immediate refinancing. The cash buffer and conservative balance sheet reduce liquidity risk and support execution of strategic partnerships and R&D initiatives.

Negative Factors

Ongoing net losses

Persistent net losses and negative operating margins limit the company's ability to self-fund growth and increase dependency on external financing or dilution. Continued unprofitability constrains reinvestment capacity and raises execution risk before sustainable margin expansion is achieved.

Weak cash generation

Negative operating cash flow and volatile free cash flow indicate inefficiencies converting revenue into usable cash. This reduces runway, increases funding needs, and makes long-term investments or scaling initiatives contingent on successful working capital management or external capital.

Profitability dependent on revenue threshold

Management's breakeven point creates binary execution risk: failure to sustain the forecasted revenue trajectory delays profitability. Achieving that threshold requires continued order conversion, pricing stability and margin discipline; any slowdown materially extends the loss-making period.

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

How the Company Makes Money

IXICO generates revenue through a business model focused on providing specialized services to pharmaceutical and biotech companies. Its key revenue streams include contracts for clinical trial services, which encompass imaging analysis and data management for drug development projects. The company often enters into partnerships or collaborations with large pharmaceutical firms, which can lead to significant project-based revenues. Additionally, IXICO may earn ongoing revenue from long-term contracts for its data analytics services, as well as through the provision of technology platforms that enhance the efficiency and accuracy of clinical trial processes. The company's ability to establish strategic alliances and maintain a strong reputation in the neuroscience field further contributes to its earnings.

IXICO plc Financial Statement Overview

Summary

Financials are mixed: income statement quality is weak with ongoing net losses and pressured margins (Income Statement Score 45), cash generation remains challenged despite some improvement (Cash Flow Score 50), while the balance sheet is comparatively steadier with low leverage (Balance Sheet Score 60). Overall, profitability and operating cash flow are the key constraints.

Income Statement

IXICO plc has experienced declining revenue over the past few years, with a slight recovery in the most recent year. The gross profit margin has decreased, indicating potential cost pressures. The company has been operating at a net loss, with negative EBIT and EBITDA margins, highlighting challenges in achieving profitability.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity has been negative, reflecting ongoing losses. The equity ratio is stable, indicating a solid equity base relative to total assets.

Cash Flow

Operating cash flow has been negative, and free cash flow has shown volatility with recent improvement. The free cash flow to net income ratio indicates challenges in converting earnings into cash flow, while the operating cash flow to net income ratio suggests inefficiencies in cash generation.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	6.53M	5.77M	6.67M	8.64M	9.19M
Gross Profit	2.91M	2.71M	3.27M	4.77M	5.53M
EBITDA	-2.02M	-1.95M	-707.00K	1.55M	1.73M
Net Income	-1.65M	-2.00M	-1.18M	1.03M	1.51M
Balance Sheet
Total Assets	13.84M	11.19M	12.99M	14.65M	14.26M
Cash, Cash Equivalents and Short-Term Investments	3.54M	1.79M	4.03M	5.77M	6.68M
Total Debt	179.00K	314.00K	387.00K	516.00K	597.00K
Total Liabilities	2.10M	1.72M	1.56M	2.16M	2.78M
Stockholders Equity	11.74M	9.46M	11.43M	12.49M	11.48M
Cash Flow
Free Cash Flow	-934.00K	-2.20M	-1.66M	-815.00K	-1.54M
Operating Cash Flow	-883.00K	-1.73M	302.00K	1.43M	614.00K
Investing Cash Flow	-870.00K	-377.00K	-1.86M	-2.25M	-2.15M
Financing Cash Flow	3.50M	-134.00K	-156.00K	-114.00K	270.00K

IXICO plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Negative. The current price of 11.75 is above the 20-day moving average (MA) of 7.95, above the 50-day MA of 9.76, and above the 200-day MA of 11.09, indicating a bearish trend. The MACD of -0.56 indicates Negative momentum. The RSI at 17.54 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IXI.

IXICO plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HVO	73 Outperform	£55.07M	-137.50	11.97%	2.94%	11.92%	-33.76%
APTA	52 Neutral	£22.25M	-3.03	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXI	51 Neutral	£7.23M	-7.18	-15.57%	―	13.32%	55.07%
PYC	48 Neutral	£1.52M	-0.72	-89.43%	―	44.32%	60.00%
OBD	45 Neutral	£10.51M	-0.25	-316.67%	―	72.17%	79.03%
AVCT	42 Neutral	£310.56M	-1.74	-361.23%	―	―	―

IXICO plc Corporate Events

IXICO Wins £1.5m Contract Extension on Phase 2 Huntington’s Trial

IXICO plc, a London-listed neuroscience imaging and biomarker analytics company, has secured an extension to an existing contract with a leading international pharmaceutical client, tied to the continued progress of a Phase 2 Huntington’s disease clinical trial. The expanded mandate underscores the appeal of its AI-driven IXI platform and deep neurological disease expertise for global biopharma customers seeking robust imaging support.

The extension is expected to deliver around £1.5 million in additional revenue over the next three years, enhancing IXICO’s visibility on mid-term income from its specialist role in neurological drug development. Management framed the deal as evidence that its technology and scientific capabilities are delivering “gold standard” outcomes, reinforcing IXICO’s positioning within the competitive imaging CRO market and providing greater operational and commercial stability as trials advance.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO Wins £1.5m Extension on Global Huntington’s Disease Trial

IXICO plc, a London-headquartered imaging Contract Research Organisation focused on neuroscience, leverages its proprietary AI-driven platform to process imaging data and quantify biomarkers in neurological disorders, supporting hundreds of trials for major pharma and biotech clients. Its IXI platform is designed specifically for neurology, aiming to reduce variability in imaging data and translate complex results into clinically meaningful insights.

The company has secured a contract extension worth about £1.5 million over three years with a leading international pharmaceutical company, tied to an ongoing global Phase 2 Huntington’s disease trial. Together with another recent win, IXICO has added more than £2.7 million in new revenues from existing clients in the past two months, underlining the commercial traction of its technology and reinforcing its role as a key partner in advancing drug development for devastating neurological conditions.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO hires US-based Chief Commercial Officer to drive growth and expand neuroimaging business

IXICO has appointed Tanya Voloshen as its new Chief Commercial Officer, a senior leadership role created to reinforce the company’s commercial capabilities and support its growth strategy, particularly in the United States, where she will be based in Boston. Voloshen brings extensive commercial and executive experience in the neuroimaging and clinical trial markets from senior roles at Perceptive Inc., Clario, QMENTA, ConcertAI and earlier positions at major pharmaceutical groups, a profile the company sees as key to deepening customer relationships and strengthening IXICO’s position in the clinical imaging market.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO Secures Strong Shareholder Backing as All AGM Resolutions Pass

IXICO plc reported that all resolutions at its Annual General Meeting were passed with overwhelming shareholder support, including the receipt of the company’s accounts, the re-election of all board directors, the reappointment of its auditor and authorities relating to the allotment of securities and the disapplication of pre-emption rights. With around 63% of issued share capital voting, the outcome underscores strong investor backing for the company’s current leadership and capital framework, providing governance continuity as it pursues its strategy in the neuroscience precision medicine and biomarker analytics market.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO plc Issues Share Options to Leadership Team

IXICO plc has announced the issuance of 1,400,000 share options to its broader leadership team, with vesting criteria tied to retention and annual revenue growth over three years. This strategic move aims to align leadership incentives with company growth objectives, potentially strengthening IXICO’s market position in the neuroscience precision medicine sector.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO plc Reports Strong Financial Growth and Strategic Expansion

IXICO plc reported a strong financial performance for the year ended 30 September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss. The company’s strategic focus on innovation, leadership, and scaling has resulted in significant commercial traction, evidenced by a 27% increase in its order book since the year-end. The company continues to expand its AI-powered platform into new industry verticals and has secured substantial contracts in Alzheimer’s and Huntington’s disease research, positioning itself for further growth in the neuroscience sector.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO plc Reports Strong Financial Growth and Strategic Expansion

IXICO plc reported strong financial results for the year ending September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss, driven by its Innovate Lead Scale strategy. The company achieved significant growth in its order book and expanded its operations in North America, while also diversifying revenue streams and enhancing its AI-powered platform. These advancements position IXICO to continue its leadership in neuroimaging and biomarker analytics, benefiting stakeholders by accelerating drug development for neurological disorders.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO Enhances Advisory Board with Alzheimer’s and Vascular Experts

IXICO plc has announced the appointment of two renowned experts in Alzheimer’s Disease and cerebrovascular disease to its Scientific Advisory Board, strengthening its focus on dementia research and product innovation, particularly in vascular biomarkers. This strategic move, unveiled at the 2025 CTAD Conference, aims to enhance IXICO’s capabilities in developing biomarker algorithms to improve clinical trial design and efficacy interpretation, thereby reinforcing its position in the neurological research community.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO plc to Announce 2025 Full Year Results and Host Investor Presentation

IXICO plc has announced it will release its Full Year Results for the year ending 30 September 2025 on 09 December 2025. The company’s CEO, Bram Goorden, and CFO, Grant Nash, will present the results and discuss the company’s progress and strategy in a live presentation open to shareholders. This announcement is significant as it provides stakeholders with insights into IXICO’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.